BRAF and NRAS are common targets for somatic mutations in benign and malignant neoplasms that arise from melanocytes situated in epithelial structures, and lead to constitutive activation of the mitogen-activated protein (MAP) kinase pathway 1,2 . However, BRAF and NRAS mutations are absent in a number of other melanocytic neoplasms in which the equivalent oncogenic events are currently unknown 3 . Here we report frequent somatic mutations in the heterotrimeric G protein a-subunit, GNAQ, in blue naevi (83%) and ocular melanoma of the uvea (46%). The mutations occur exclusively in codon 209 in the Ras-like domain and result in constitutive activation, turning GNAQ into a dominant acting oncogene. Our results demonstrate an alternative route to MAP kinase activation in melanocytic neoplasia, providing new opportunities for therapeutic intervention.
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Most melanocytic neoplasms-benign melanocytic naevi as well as melanomas-originate from melanocytes situated within epithelial structures throughout the body, mostly the sun-exposed skin of individuals with light complexion. Most naevi and melanomas show oncogenic mutations in signalling components of the MAP kinase pathway, in particular BRAF and NRAS (refs 1, 2). However, a subset of melanocytic neoplasms does not show mutations in BRAF and NRAS (ref. 3) . One category, uveal melanoma, arises from melanocytes within the choroidal plexus of the eye and is biologically distinct from cutaneous melanoma by characteristic cytogenetic alterations 4 and a very strong propensity to metastasize to the liver 5 . The other category comprises intradermal melanocytic proliferations, which can be congenital or acquired, and present in diverse ways ranging from discrete bluish moles (blue naevi) to large blue-grey patches affecting the conjunctiva and periorbital skin (naevus of Ota), shoulders (naevus of Ito) and the lower back (Mongolian spot) 6 . A potential connection between intradermal melanocytic neoplasms and uveal melanoma is suggested by the fact that naevus of Ota is a risk factor for uveal melanoma and by an overlap in some of the histomorphological features of the two conditions 7 .
Using a forward genetic screen in mice we previously identified hypermorphic mutations in Gnaq or Gna11 as a cause of diffuse skin hyperpigmentation that was due to an increase of intradermal, but not epidermal, melanocytes 8 . GNAQ and GNA11 encode members of the q class of G-protein a-subunits involved in mediating signals between G-protein-coupled receptors (GPCRs) and downstream effectors. To investigate whether similar pathways were involved in humans, we sequenced the entire coding regions of GNAQ and GNA11 in a broad spectrum of benign and malignant melanocytic neoplasms. We found mutations in GNAQ in 83% of blue naevi (n 5 29), 50% of 'malignant blue naevi' (n 5 2) and 46% of uveal melanomas (n 5 48) (Table 1 and Supplementary Fig. 1a ). Naevus of Ota is a condition in which a subtle proliferation of intradermal melanocytes results in hyperpigmentation of the conjunctiva and periorbital skin. To increase the detection limit for mutations in a background of normal cells, we used a mutation-specific assay and found a mutation in one of 14 cases (6%; Supplementary Fig. 1b ). No somatic point mutations were found in GNA11.
All mutations in GNAQ were somatically acquired as assessed by sequencing DNA from adjacent tissue, and occurred exclusively at codon 209 (Supplementary Table 1 ). The glutamine at codon 209 lies within the ras-like domain of GNAQ (corresponding to residue 61 of Ras) and is essential for GTP hydrolysis 9 . In Ras family members, mutations at this site, and at codon 12, cause loss of GTPase activity with constitutive activation [9] [10] [11] . There is no equivalent of codon 12 in GNAQ. In contrast to the findings in humans, the mutations found in the dark-skinned mice occurred at I63, V179 and F335 in the mouse proteins and do not cause constitutive activation 8 .
So far, no mutations of GNAQ have been described in human neoplasia, but GNAQ Q209L has been demonstrated to transform 3T3 cells 11 . In addition, mutations of the corresponding codon in Ga s (GNAS) are found in human pituitary and thyroid tumours 10, 12 . To assess the effect of GNAQ Q209L on human melanocytes, we established epitope-tagged lentiviral expression constructs to transfect normal and genetically The number and type of samples analysed is shown.
modified human melanocytes. The latter have an extended lifespan through transduction with telomerase (hTERT) and inactivation of their p53 and p16/CDK4/RB pathways, but still require additional factors (cyclic AMP, 12-O-tetradecanoylphorbol-13-acetate (TPA)) for growth (hereafter called hTERT/CDK4 R24C /p53 DD melanocytes 13 ). Stable transfection of GNAQ Q209L into primary human melanocytes was insufficient to induce anchorage-independent growth (data not shown). In contrast, transfection of GNAQ Q209L into hTERT/ CDK4 R24C /p53 DD melanocytes resulted in anchorage-independent growth with efficiencies comparable or slightly greater than transfection with NRAS Q61R (Fig. 1a and Supplementary Table 2 ). Furthermore, GNAQ Q209L but not wild-type GNAQ induced abnormally enlarged nuclei with markedly irregular contours ( Fig. 1b and Supplementary Table 3 ). To validate GNAQ Q209L as an oncogene in vivo, we performed tumorigenicity studies in nude mice ( Fig. 1c ). GNAQ Q209L , but not wild-type GNAQ or vector-control-transfected melanocytes, gave rise to heavily pigmented tumours at the injection site. The tumour morphology resembled closely the spectrum of atypical blue naevus that in humans has been termed animal type melanoma or pigmented epithelioid melanocytoma 6 .
Signalling pathways downstream of GNAQ include activation of protein kinase C family members via the release of diacylglycerol (DAG) by phospholipase Cb. Consistently, GNAQ Q209L -transformed melanocytes grew in soft agar in the absence of TPA, a synthetic DAG analogue ( Fig. 1a and Supplementary Table 2 ). Protein kinase C activation by way of GNAQ activation can activate the MAP kinase pathway in other cell types 14 . Uveal melanomas show MAP kinase activation 15 , but none of the uveal melanomas we examined in our study showed mutations in BRAF or NRAS ( Supplementary Table 4 ), consistent with other studies 3 . We therefore tested whether GNAQ Q209L would contribute to MAP kinase pathway activation in human melanocytes and uveal melanoma cells. As shown in Fig. 2 , GNAQ Q209L transfection into hTERT/CDK4 R24C /p53 DD melanocytes caused increased levels of phosphorylated ERK compared with control cells transfected with wild-type GNAQ or an empty vector. Similar results were obtained with GNAQ Q209L transfection into primary human melanocytes and 293T cells ( Supplementary Fig. 2 ). Conversely, short interfering RNA (siRNA)-mediated knockdown of GNAQ in the uveal melanoma cell line OMM1.3, which harbours the GNAQ Q209L mutation, resulted in a decrease of phosphorylated ERK levels (Fig. 3a ). In addition, GNAQ knockdown in OMM1.3 cells causes a substantial decrease in cell number (Fig. 3b ), loss of anchorage-independent growth (Fig. 3c ) and a marked increase in sub-G0/ G1 population (Fig. 3d ) as compared with control cells. Similar results were obtained when another uveal melanoma cell line, Mel202, was treated with siRNA against GNAQ Q209L ( Supplementary Fig. 3 ). Mel202 and OMM1.3 stem from different patients, as confirmed by DNA fingerprinting (data not shown). Our data identify GNAQ as a novel oncogene in human neoplasia. GNAQ operates downstream of several GPCRs that are important in melanocyte homeostasis and neoplasia. GNAQ is involved in endothelin signalling, which is essential for melanocyte survival early during development 16 . G q signalling may also contribute to the association observed for melanoma invasion and metastasis with Wnt family members 17 , as frizzled receptors can couple to G q 18 . Furthermore, G q signalling probably underlies the ability of the metabotropic glutamate receptor gene, Grm1, to cause dermal melanocytic neoplasia and ocular melanoma in transgenic mice 19 .
The location of neoplastic melanocytes induced by somatic GNAQ mutation in humans is very similar to the location of melanocytes affected by germline Gnaq (and Gna11) mutations in mice 8 . In both cases, the melanocytic proliferations spare epithelial structures. However, our previous work in mice suggests that these mutations do not interfere with homing of melanocytes to epithelial structures, but instead lead to an increase of the total melanoblast pool 8 . In humans, it is not known whether the adult dermis contains any residual sparse populations of melanocytes in which GNAQ mutations could occur and induce intradermal melanocytic tumours 6, 20 .
Acquired blue naevi are typically small and well circumscribed, raising the possibility that they arise from an intradermal population of melanocytes that remains to be characterized. By contrast, naevus of Ota involves different structures such as periorbital skin, conjunctiva, neurovascular bundles, ganglia and uvea, suggesting that these GNAQ mutations may arise early in a migrating melanoblast. This later neoplasm shows strong similarities to the murine studies and indicates a specific window for G q signalling in terms of cell type and developmental time that is conserved across species.
Our findings identify GNAQ as a genetic link between naevus of Ota and uveal melanoma and help to explain why naevi of Ota are a risk factor for uveal melanoma 7 . The risk is small, as only about 1 in 400 naevi of Ota progress to uveal melanoma, and future studies will have to elucidate the role of GNAQ mutations in this risk. In our experiments, GNAQ behaves similarly to the oncogenes BRAF and NRAS in that its mutation is insufficient for full progression to melanoma. This is illustrated best by blue naevi, which are generally stable lesions that rarely become malignant ('malignant blue naevus') 6 . Thus, MAP kinase activation seems to be an early event in neoplasms with GNAQ mutations, as it is in neoplasms with BRAF and NRAS mutations 2 . Further studies are necessary to determine whether the difference in tissue involvement between melanocytic neoplasms with BRAF mutations and those with GNAQ mutations is a functional consequence of the mutations themselves, or indicates differences in the target cell populations in which these mutations occur.
Uveal melanoma is a highly aggressive cancer without any effective treatment options once it metastasizes. Although it only accounts for approximately 5% of all melanomas, it represents the most common intraocular malignancy in the United States and has a 5-year diseasespecific survival rate of approximately 70% 21 . Our study identifies signalling components downstream of GNAQ as potential targets in this disease.
METHODS SUMMARY
GNAQ and GNA11 were sequenced in DNA extracted from archival, paraffinembedded biopsies under the approval of the institutional review boards at UCSF, Stanford and University of British Columbia (UBC). Primary, hTERT/ CDK4 R24C /p53 DD and melan-a melanocytes were stably infected with FG12 lentiviral expression vectors expressing Flag-tagged wild-type GNAQ or GNAQ Q209L , empty vector or NRAS Q61R . Infection efficiencies were estimated by the proportion of cells expressing GFP. To assess anchorage-independent growth, melanocytes were plated on soft agar, cultured for 28 days and stained with 0.005% crystal violet. For tumorigenicity experiments, one million lentiviral transfected melan-a cells were injected into each nude mouse, housed at UBC according to CCAC guidelines. For immunofluorescence, lentiviral transfected cells were cultured on coverslips for 5 days and incubated with antibodies against pERK (E-4, Santa Cruz Biotechnology), cyclin D1 (M-20, Santa Cruz Biotechnology) and GNAQ (C-19, Santa Cruz Biotechnology). OMM1.3 and Mel202 cells were transfected with two different pools of siRNA against GNAQ: pool 1, 59-CAAUAAGGCUCAUGCACAAUU-39, 59-CGACGAGAAUAUCA-AUUAUUU-39, 59-GCAAGAGUACGUUUAUCAAUU-39, 59-UAGUAGCGC-UUAGUGAAUAUU-39; pool 2, 59-AUGCACAAUUAGUUCGAGAUU-39, 59-UAUGAUAGACGACGAGAAUUU-39, 59-CAGACAAUGAGAACCGAAU-UU-39, 59-CGCCACAGACACCGAGAAUUU-39. For western blot analysis, 5-20 mg of protein was extracted from lentiviral or siRNA transfected cells. Primary antibodies were: pERK, cyclin D1, GNAQ, cyclophilin B (Abcam), anti-Flag M2 (Sigma), anti-ERK1/2 pAb (Promega), and b-actin (Sigma). Secondary antibodies were labelled with horseradish peroxidase. Relative cell numbers were quantified by the CyQUANT cell proliferation assay kit (Invitrogen). Cell cycle measurements were performed on a FACSCalibur after staining with propidium iodide. Student's t-test and Fisher's exact test were used for statistical comparison. 
